CD8A and relapsing-remitting multiple sclerosis: Treatment with 2-DG, a glucose analogue, leads to reduced activation of CD8+ T cell subsets in RRMS patients, as proved by decreased expression of the early activation marker CD69, reduced levels of the high-affinity IL-2 receptor CD25, and lower production of TNF α [103].